The Office of Information and Regulatory Affairs (OIRA) recently updated its dashboard to disclose that the SEC had submitted a rulemaking titled “Rescission of Climate-Related Disclosure Rules” for review. Once the OIRA review is complete, the Commission will then consider
Latest from Goodwin Procter - Page 11
SEC Proposes Amendments to Permit Optional Semiannual Reporting by Public Companies
The SEC proposed amendments (summarized in this Fact Sheet) that would allow public companies to elect to file semiannual reports on new Form 10-S, rather than filing quarterly reports on Form 10-Q. The SEC also proposed amendments to the
Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion
On April 22, 2026 Amneal Pharmaceuticals, Inc. announced that it entered into an agreement to acquire Kashiv BioSciences, LLC. Under the terms of the agreement, Amneal will pay $375 million in cash and $375 million in equity at closing, along
Eli Lilly to Acquire Kelonia Therapeutics
On April 20, 2026, Eli Lilly & Company (“Lilly”) and Kelonia Therapeutics, Inc. (“Kelonia”) announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expected to close in the second half of 2026. Under the terms of the
Sun Pharma to Acquire Organon
On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon in an all-cash transaction valued at $11.75 billion and expected to close
AbbVie Regulatory Submission and Deal News
AbbVie Submits Regulatory Application to FDA for Subcutaneous SKYRIZI
On April 27, 2026, AbbVie announced that it has submitted a regulatory application to the FDA seeking approval for SKYRIZI (risankizumab-rzaa) for subcutaneous induction for the treatment of adult patients with moderately
Edwin O’Connor Participates in SEC’s Small Business Capital Formation Advisory Committee Meeting
On April 28, 2026, Edwin O’Connor, Co-Chair of Goodwin’s Capital Markets practice, participated in the SEC’s Small Business Capital Formation Advisory Committee meeting, where he joined a panel focused on encouraging more initial public offerings (IPOs), particularly among small and
Shareholder Proposals and ESG at a Crossroads: What Boards Should Know After the 2026 Proxy Season
The Weinberg Center’s fifth annual “ESG in the Boardroom” program, titled “Shareholder Proposals at the Crossroads: Boards, ESG, and the Future of SEC Rule 14a-8,” held April 28 in Wilmington, Delaware, brought together directors, jurists, advisors, and regulators to examine
Public Company Advisory News Roundup: SEC Staff Shortens Minimum Tender Offer Period for Certain All-Cash Offerings to 10 Business Days
The latest issue of the Goodwin Public Company Advisory News Roundup has been posted, covering the period from April 10, 2026 – April 24, 2026. The Roundup highlights the latest developments in SEC and stock exchange regulatory activity, corporate governance and
Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema
On April 27, 2026, Intellia Therapeutics (“Intellia”) announced that it has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), an investigational therapy for hereditary angioedema (HAE). Lonvo-z, previously known as NTLA-2002,
